Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 14 August 2003
Further patent for LentiViral gene
therapy
Oxford BioMedica has received allowance from the US Patent Office for a further patent covering its proprietary LentiVector technology
This additional patent complements the US patent 6,312,682 issued in November 2001 and both include broad composition of matter claims and methods of production claims for lentiviral vector gene delivery systems of both human and non-human origin This patent adds further strength to Oxford BioMedica's existing patents that cover derivatives of lentiviral vector systems that, unlike many versions of lentiviral vectors, have real clinical utility because of their safety
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
The Oxford BioMedica team was the first to construct lentiviral vectors that contain no viral genes at all, and which comprise the minimum number of viral components in the viral particles.
It is this minimisation of the vectors that is the subject of these patents.
This work was done using vectors based on HIV and Equine Infectious Anaemia Virus (EIAV), a horse virus that is not linked to any disease in humans.
Further reading
Phase II results with Trovax are 'encouraging'
Oxford BioMedica, a gene therapy company, reported that encouraging data from five Phase II studies of Trovax, its lead cancer immunotherapy product, were presented at the annual meeting of Asco
Lentivector licensing agreement signed
Oxford BioMedica has signed a further licence agreement for its LentiVector technology with a large biopharmaceutical company
The EIAV system is Oxford BioMedica's system of choice because of its superior safety profile.
Oxford BioMedica's LentiVector gene delivery technology is arguably the most potent system currently available for treating diseases of the central nervous system, particularly chronic neurodegenerative disorders.
Oxford BioMedica has shown that minimal lentiviral vectors are able to deliver genes to a wide range of dividing and non-dividing cells, including neurones in the brain.
This technology forms the delivery system for several of the company's products that are approaching the clinical development stage.
ProSavin, for Parkinsons disease, is Oxford BioMedica's most advanced programme that uses the proprietary LentiVector gene delivery system.
In addition to ProSavin, there are three further research/preclinical stage programmes using the LentiVector system: RetinoStat, for retinopathy (vision loss), Innurex, for nerve repair in spinal cord injury, and MoNuDin, for motor neuron disease.
"Oxford BioMedica's LentiVector technology is a powerful gene delivery platform that out-performs other vector systems in terms of its combination of high gene transfer efficiencies, duration and regulation of gene expression, ease of production and safety.
"This is reflected in the range of commercial discussions that are underway related to this technology, and in encouraging results from a number of the company's preclinical studies.
"We are working currently on taking our first LentiVector-based product into clinical trials for Parkinson's disease" said Alan Kingsman, chief executive of Oxford BioMedica.
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
